ASCL2 and colonic neoplasm: Together, these results demonstrate that KISIMA-Mash2 vaccine, when combined with an immune checkpoint blockade (anti-PD-1 treatment), induces Mash2-specific T cells, which are able to infiltrate the colon and reduce the formation of colon tumors.